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Purpose: Nitric oxide (NO) is important in regulation of platelet aggregation, endothelial function, and intravascular
thrombosis. The purposes of this study were to assess the effect of thrombolysis on endothelial function in a porcine
model of deep venous thrombosis (DVT) and to evaluate the effect of NO precursor L-arginine on endothelial function
after thrombolytic therapy.
Methods: DVT was created in bilateral iliac veins by deploying a self-expanding stent-graft that incorporated an
intraluminal stenosis, from a groin approach. Five pigs underwent sham operation. After 7 days of DVT, animals
were randomized to three groups: saline pulse-spray (saline group, n  5), thrombolytic pulse-spray with tissue
plasminogen activator (alteplase, 8 mg; t-PA group, n  5), and thrombolytic pulse-spray plus intravenous
L-arginine (20 mmol/L; arginine group, n  5). At 2 weeks iliac vein patency was evaluated at venography and
intravascular ultrasound scanning. NO level was determined with a chemiluminescent assay of the nitrite and nitrate
metabolites (NOx). Thrombogenicity was evaluated with radiolabeled platelet and fibrin deposition. Veins were
harvested and evaluated with light microscopy and scanning electron microscopy. Endothelial function was
evaluated with organ chamber analysis.
Results: All iliac veins remained patent at 2 weeks. The luminal areas in the sham, saline, t-PA, and arginine groups were
53  23 mm2, 14  11 mm2, 34  19 mm2, and 42  21 mm2, respectively. No difference in endothelial cell structure
was observed between the three treatment groups at light microscopy or scanning electron microscopy. Although no
difference in fibrin deposition was noted among the three treatment groups, decreased platelet deposition occurred in the
arginine group compared with the saline or t-PA groups (P < .05). The arginine group showed greater endothelial-
dependent relaxation compared with the t-PA or saline groups (73% 23% vs 49% 18% and 32% 21%; P < .05). Local
NOx level in the arginine group was correspondingly higher compared with the saline or t-PA groups (1.8 0.3 mol/L
vs 0.3  0.05 mol/L and 0.2  0.04 mol/L; P < .05).
Conclusions: NO precursor L-arginine supplementation enhances NO production at sites of venous thrombosis. More-
over, L-arginine preserves endothelial vasoreactivity and reduces platelet deposition after thrombolysis in iliac DVT.
These data suggest that L-arginine may preserve endothelial function after thrombolysis and may reduce the likelihood of
postthrombotic syndrome. (J Vasc Surg 2003;38:1396-403.)
Deep venous thrombosis (DVT) is estimated to affect
20% to 30% of all patients who undergo major surgery, and,
as a result of pulmonary embolism, is responsible for more
than 60,000 deaths annually in the United States.1,2 Cath-
eter-directed thrombolytic therapy has been embraced by
physicians as effective treatment of this disease. However,
the physiologic response of the venous endothelium to
thrombosis and thrombolytic therapy has not been widely
investigated. The vascular endothelium produces a variety
of vasoactive substances, including nitric oxide (NO), en-
dothelin-1, and prostacyclin, that influence thrombogenic-
ity and the vasomotor response of underlying smooth mus-
cle cells.3,4 Production of these endothelium-derived
factors is significantly altered in venous thrombosis.5 A
recent study that analyzed cellular function in acute DVT
after thrombotic therapy revealed that greater endothelial
functions were preserved after thrombolysis compared with
thrombectomy.6 This phenomena may be mediated in part
by endothelium-derived vasoactive substance such as NO,
which is generated by enzymatic oxidation of the amino
acid L-arginine into L-citrulline through the action of NO
synthase.7 L-arginine modulates the thrombotic process
and inhibits platelet aggregation.8,9 We recently character-
ized an experimental model of DVT created with an endo-
vascular stent graft, and also demonstrated that this chronic
DVT model was amenable to catheter-directed thrombo-
lytic therapy.10 The present study was designed to assess the
effect of thrombolytic therapy on endothelial function in
chronic DVT and to evaluate the effect of NO precursor
L-arginine on endothelial function after thrombolytic ther-
apy.
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MATERIAL AND METHODS
Animal model and interventions. Twenty adult do-
mestic swine, each weighing 45 to 50 kg, were used in all
experiments. All animal procedures and care were per-
formed in accordance with the Guide for the Care and Use
of Laboratory Animals (Institute of Laboratory Animal
Resources, National Research Council. Washington, DC:
National Academy Press; 1996). Animals were given intra-
venous thiopental sodium (10 mg/kg). Endotracheal intu-
bation was performed, and anesthesia was maintained with
1% isoflurane. Under sterile conditions, bilateral groin cut-
down incisions were made, to expose the superficial femoral
veins, followed by placement of a 14F introducer sheath
(Meditech, Watertown, Mass). Bilateral DVT was created
with use of an endovascular model previously described.10
In brief, a self-expanding nitinol stent graft (Symphony
Stent; Meditech) that incorporated intrastent stenosis was
deployed in bilateral common iliac veins. The intrastent
stenosis was created with a tapered polytetrafluoroethylene
graft (W. L. Gore & Associates, Flagstaff, Ariz), which
caused flow stasis with resultant DVT (Fig 1). An infrarenal
Greenfield vena cava filter (Meditech) was also placed in
each animal, to prevent pulmonary embolism (Fig 1).
Venography was performed, which documented the pres-
ence of DVT in bilateral iliac veins. The introducer sheaths
were removed, and the venotomy was closed with 6-0
polypropylene suture, followed by layered groin wound
closure. Endotracheal extubation was performed, and the
animals were allowed to recover after stent-graft
deployment.
The animals were divided into four groups, with 5
animals in each group. The first group underwent sham
operation without stent-graft placement (sham group); the
remaining 15 animals underwent bilateral stent-graft place-
ment to induce DVT. After 7 days of DVT, the remaining
15 animals were divided into three groups: one group
received saline pulse-spray thrombolysis (saline group);
another group received thrombolytic pulse-spray with tis-
sue plasminogen activator (t-PA; Alteplase, Genentech, San
Francisco, Calif; t-PA group); and the third group received
thrombolytic pulse-spray plus intravenous L-arginine
(Sigma, St Louis, Mo; arginine group).
The thrombolytic pulse-spray procedure was per-
formed with techniques previously described.10-13 In brief,
animals were given general anesthesia after endotracheal
intubation, and bilateral groin incisions were made, fol-
lowed by placement of 7F introducer sheaths (Meditech).
A 0.035-inch Bentson guide wire (Meditech) was inserted
through the introducer sheath in the femoral vein to can-
nulate the stent graft in the iliac vein. A 6F Mewissen
infusion catheter (Meadox, Oakland, NJ) was placed over
the guide wire and positioned across the tapered stent graft,
and pulse-spray therapy was administered to iliac vein
thrombus both above and below the stent graft. In the t-PA
group, 8 mg of alteplase was mixed with 20 mL of sterile
water and pulse-sprayed via the Mewissen catheter by man-
ually injecting a 0.2-mL aliquot every 30 seconds with a
tuberculin syringe. In the arginine group, 100 g/kg of
L-arginine was mixed with 10 mL of sterile water, which
was pulse-sprayed in the iliac veins after t-PA thrombolysis.
The L-arginine infusion dose was chosen from previous
reports.14,15 After pulse-spray thrombolysis, balloon angio-
plasty was performed with a 12-mm 4-cm balloon (XXL;
Meditech), to dilate the tapered stent graft, which elimi-
nated the intrastent stenosis and restored venous flow. Iliac
vein patency was assessed at venography and intravascular
ultrasound scanning (IVUS).
Two weeks after pulse-spray thrombolytic therapy, an-
imals in all groups were anesthetized. Bilateral femoral
veins were exposed, followed by placement of 7F intro-
ducer sheaths (Meditech). Iliac vein patency was assessed at
venography and IVUS. Laparotomy was performed to har-
vest the entire ileofemoral veins. Histologic analysis and
organ chamber study were performed in one ileofemoral
vein, and local thrombogenicity was evaluated in the con-
tralateral vein before vein harvesting. All histologic and
functional analyses of the iliac veins were performed in vein
segments just below the stent-graft placement site, where
thrombosis and pulse-spray thrombolytic therapy occurred.
IVUS. A 3.5F 20 MHz IVUS catheter was inserted
over the guide wire with a ClearView Ultra Intravascular
Fig 1. Tapered polytetrafluoroethylene graft was inverted within
the nitinol stent to create intrastent stenosis, which was deployed
in the common iliac vein to cause venous thrombus due to flow
stasis. Large arrow, location of stent graft (inset) deployed to cause
iliac venous thrombosis. A Greenfield filter was placed in the
infrarenal vena cava to prevent pulmonary embolism (small arrow).
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Ultrasound System (Meadox). Before pulse-spray throm-
bolytic therapy, IVUS was performed to assess the iliac
venous thrombus by a clinician blinded to the respective
treatment groups. The IVUS catheter was first inserted in
the proximal iliac vein just below the stent-graft, and five
different images were obtained in the proximal 2 cm of each
iliac vein for thrombus measurement. After thrombolysis,
the IVUS catheter was again positioned within the proxi-
mal 2 cm of the iliac vein to obtain five different images for
residual thrombus measurement. Spot fluoroscopic images
were used to confirm the location of the IVUS transducer
within the proximal iliac vein. The luminal dimensions
before (Before) and after (After) pulse-spray thrombolysis
were traced on the IVUS image with a tracking device,
which allowed calculation of a cross-sectional area:
Efficacy of thrombolytic therapy(%)  1
 ( AreaAfter/AreaBefore)  100
Organ chamber evaluation. Evaluation of endotheial
vasoreactive functions with the organ chamber myograph
system has been described in our laboratory.16-18 Through
an abdominal and bilateral groin exposure, one iliofemoral
vein was carefully harvested in its entirety before injection
of radiolabeled platelets and fibrinogen. The iliac vein
proximal to the nitinol stent was sectioned into multiple
5-mm segments, which were incubated in Dulbecco mod-
ified Eagle medium at 37°C and 5% CO2 in a cell culture
incubator. After culture, rings were suspended between the
wires of the organ bath myograph chamber (Organ Bath
700MO; Danish MyoTechnology, Aarhus, Denmark) in 8
mL of Krebs solution (NaCl, 120 mmol/L; MgSO4, 1.17
mmol/L; KH2PO4, 1.18 mmol/L; NaHCO3, 25
mmol/L; CaCl2, 2.5 mmol/L; KCl, 4.7 mmol/L; glucose,
5.5 mmol/L) maintained at 37°C, and oxygenated with
pure oxygen gas to maintain pH 7.4. Rings were subjected
stepwise to a predetermined optimal tension of 2g and
allowed to equilibrate for at least 60 minutes. After equili-
bration, each ring was precontracted with norepinephrine,
104 mol/L; Sigma) and allowed to re-equilibrate to pro-
duce the maximal contractile force (Fmax) for the vessel.
The organ baths were rinsed with Krebs solution, and the
vessels were contracted to 75% of Fmax with norepineph-
rine. The vessels were challenged with adenosine diphos-
phate (ADP; Sigma) in an incremental log concentration
from 109 to 104 mol/L to determine endothelial-de-
pendent relaxation.
In addition, vessels were challenged with calcium chan-
nel ionophore A23187 (109 to 106.5 mol/L), an endo-
thelial-dependent vasodilator, and allowed to equilibrate
for 10 minutes to assess endothelial-dependent relaxation.
Relaxation dose-response curves were also determined with
incremental additions of endothelium-dependent vasodila-
tor bradykinin (107 to 104.5 mol/L). Endothelial-inde-
pendent relaxation was assessed with addition of sodium
nitroprusside (Sigma), from 107 to 105 mol/L, which
influenced smooth muscle cell relaxation. Baths were
rinsed, and vein segments were brought to 50% Fmax with
norepinephrine between each reagent. Contractility and
percentage of relaxation were calculated on the basis of
tension change.
Data for all iliac vein segments from each animal were
averaged, and represented as 1 data point for statistical
analysis.
Thrombogenicity. Blood samples from each animal
were obtained and placed in anticoagulant-citrate-dextrose
solution (ACD solution, modified; Squibb Diagnostics,
New Brunswick, NJ) for centrifuge to acquire platelet
pellet. Platelet sample was resuspended with ACD solution,
followed by indium 111 oxyquinoline (Amersham Corp,
Arlington Heights, Ill) to create radiolabeled platelets.
Freeze-dried human fibrinogen labeled with iodine 125
(Amersham Corp) was reconstituted in 1.1 mL ACD solu-
tion. After harvesting of one iliofemoral vein for organ
chamber analysis, the radiolabeled platelet and fibrinogen
were injected into the animal and allowed to circulate for 3
hours before harvesting of the contralateral iliofemoral
vein. The vein segment was cut into three sections with
documented surface areas. Depositions of 111In-labeled
platelets and 125I-labeled fibrinogen were analyzed in each
iliac vein segment, in accordance with the surface area, with
a gamma counter (Packard Instruments, Downers Grove,
Ill). Hemocytometry was performed to determine platelet
concentration. Formulas used to calculate platelet and fi-
brin deposition were chosen from published reports.6,19
Histologic analysis and immunohistochemistry.
Segments of the iliac vein were fixed in 10% buffered
formalin overnight, then transferred to 70% alcohol. The
specimens were dehydrated with sequentially increasing
concentrations of ethanol followed by xylene, and embed-
ded in paraffin. Five-micrometer cross sections were cut
and prepared as described.20,21 Histologic staining with
hematoxylin-eosin, methylene blue, and Verhoeff-Masson
stains were performed. Immunohistochemical analysis was
performed with the avidin-biotin complex immunoperoxi-
dase procedure (LSAB Kit; DAKO, Carpenteria, Calif) as
described.20,21 Immunostaining for -actin and factor
VIII-related antigen was performed to identify smooth
muscle cells and endothelial cells, respectively.
For scanning electron microscopy (SEM; Cambridge
360 SEM microscope, Cambridge, United Kingdom), the
iliac vein segment was incised to allow en face imaging. This
tissue specimen was placed in 2% glutaraldehyde and fixed
overnight. The specimens were rinsed in phosphate-buff-
ered saline solution three times, and dehydrated in a graded
series of ethanol (30%-100%). Tissue samples were placed
with a graded series of hexamethyldisilazane, air-dried, and
gold sputter–coated before imaging. Endothelial loss based
on SEM images was scanned and evaluated by a blinded
observer using SEM image software (Bioview Image, At-
lanta, Ga).
Nitric oxide evaluation. NO level was determined
with a chemiluminescent detector. For systemic NO anal-
ysis, samples of venous blood from the superficial ear vein of
each animal were assayed before pulse-spray therapy, 4
hours after pulse-spray therapy, and before tissue harvest.
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Blood specimens were centrifuged at 3600 rpm to yield
plasma, which was analyzed in a chemiluminescence detec-
tor (NOx analyzer, Model 2108; Dosibi Environmental,
Glendale, Calif). NO concentration was determined by
reconverting its oxidation end products nitrite (NO2) and
nitrate (NO3). Routine calibration of the chemilumines-
cence detector was performed with a known NO sample
value during each sampling analysis. To determine local
NO production, 1-cm segments of iliac veins were har-
vested and suspended in physiologic Krebs buffer for 10
minutes just before the animals were killed. One milliliter of
buffer was drawn and refrigerated at 4°C for subsequent
assay. All samples were performed in triplicate.
Statistical analysis. Values are expressed as mean 
SEM. Differences in vessel relaxation and contraction in
organ chamber studies, and deposition of platelet and fibrin
in thrombogenicity studies were determined with one-way
analysis of variance or Student t test, where appropriate. A
SAS statistical package was used for analysis (SAS Inc, Cary,
NC). P  .05 was considered statistically significant.
RESULTS
All iliac veins remained patent at 2 weeks after pulse-
spray treatment. A wide disparity of iliac venous thrombotic
regions was detected with IVUS among the treatment
groups. At 2 weeks after pulse-spray treatment, luminal area
was 53 23 mm2 in the sham group, 14 11 mm2 in the
saline group, 34 19 mm2 in the t-PA group, and 42 21
mm2 in the arginine group. Thrombolytic efficacy and
thrombus areas calculated with IVUS are summarized in
Table I.
Light microscopy and SEM. Histologic evaluation
of thrombus revealed the presence of recanalized and orga-
nized thrombus in the saline group (60%, 3 of 5 animals),
t-PA group (40%, 2 of 5 animals), and arginine group (60%,
3 of 5 animals). In contrast, the control specimen did not
contain any recanalized thrombus (0%, 0 of 5 animals; P
.05). Immunohistochemistry revealed a similar pattern of
factor VIII staining in all groups, without obvious evidence
of endothelial cell loss. Immunohistochemical staining of
-actin showed a positive staining pattern in the thrombus
and media, without evidence of intimal proliferation, in all
groups. SEM evaluation revealed similar patterns of endo-
thelial cell loss among the three treatment groups (saline,
34% 21%; t-PA, 36% 18%; arginine, 29% 16%). The
control group showed minimal endothelial denudation
(12%  8%) compared with the three treatment groups.
When analyzing the inflammatory response on the basis of
histologic findings, a significant increase in leukocytes, with
a relatively equal presence of neutrophils and macrophages,
was found in the saline, t-PA, and arginine groups com-
pared with the sham control group.
NOx level. Systemic NOx measurement based on a
chemiluminescent assay immediately after pulse-spray
thrombolysis showed no difference between groups (P 
.05). Similarly, no differences in systemic NOx levels were
detected between groups at tissue harvest 14 days later.
However, local NOx level in the arginine group was corre-
spondingly higher compared with the sham, saline, or t-PA
groups (P  .05; Table II).
Thrombogenicity. No differences in preoperative he-
matocrit or platelet counts were noted between groups.
Platelet count was 259,300/L in the control group,
319,400/L in the saline group, 284,500/L in the t-PA
group, and 331,600/L in the arginine group. Hematocrit
was 41.3% in the control group, 42.6% in the saline group,
49.3% in the t-PA group, and 46.7% in the arginine group.
Two weeks after pulse-spray thrombolysis, radiolabeled
fibrin deposition did not differ between groups. However,
a decrease in platelet deposition was noted in the arginine
group compared with either the t-PA or saline groups (P
.05; Table III).
Organ chamber studies. Maximal contraction curves
in response to norepinephrine were similar in all tested
groups at 104 mol/L, with mean Fmaxrange 4.3  1.2 to
5.3  1.4 g. Calcium ionophore A23187 caused concen-
tration-dependent relaxation in all tested groups. The argi-
nine group exhibited a greater relaxation response at 106
mol/L compared with the t-PA or saline groups (75% 
22% vs 52%  21% and 48%  16%; P  .05; Fig 2). No
significant difference was found in endothelial-dependent
relaxation in response to calcium ionophore A23187 be-
tween the arginine and control groups (Fig 2). Endothelial-
dependent relaxation was also assessed by adding bradyki-
nin in log escalating doses. The t-PA, arginine, and saline
groups showed a similar response curve in a concentration-
dependent fashion (Fig 3). ADP caused concentration-
dependent relaxation in iliac venous segments in all groups.
The arginine group exhibited greater relaxation compared
with the t-PA or saline groups in response to ADP at 104
Table I. Intravenous ultrasound evaluation of thrombus
areas and thrombolytic efficacy after pulse-spray
thrombolytic therapy
Group
Pre-thrombolysis
thrombus area
(mm2)
Post-thrombolysis
thrombus area
(mm2)
Thrombolytic
efficacy (%)
Sham 14.4  4.4 3.5  1.7 79
Saline 71.4  13.4 61.7  16.7 14
t-PA 82.9  15.5 32.4  12.3 61*
Arginine 77.8  18.9 16.9  8.4 78*
t-PA, Tissue plasminogen activator.
*P  .05 compared with saline pulse-spray group.
Table II. Systemic and local NOx in all groups
Group
Systemic NOx level
(mol/L)
Local NOx level
(mol/L)
Sham 32.3  14.5 0.3  0.1
Saline 35.6  18.3 0.2  0.1
t-PA 27.3  17.8 0.4  0.2
Arginine 32.6  15.4 1.8  0.5*
NOx , Nitric oxide metabolites; t-PA, tissue plasminogen activator.
*P  .05 compared with sham, saline, and t-PA pulse-spray groups.
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mol/L concentration (73%  23% vs 49%  18% and 32%
 21%; P  .05; Fig 4). The control group exhibited the
greatest degree of endothelial-dependent relaxation in re-
sponse to bradykinin and ADP when compared with the
arginine, t-PA, and saline groups (Figs 3, 4). Endothelial-
independent relaxation was assessed by determining the
relaxation response to log escalating doses of sodium nitro-
prusside. All vein segments responded similarly to sodium
nitroprusside in a concentration-dependent manner (Fig
5).
DISCUSSION
Numerous clinical reports have shown that early reso-
lution of deep venous thrombus is beneficial in improving
clinical outcome, due in part to maintenance of valve
competency and reduction of subsequent likelihood of
post-thrombotic syndrome.22-24 Resolution of venous
thrombus can occur through spontaneous thrombolysis,
mechanical thrombectomy, or catheter-directed thrombo-
lytic therapy. Several experimental studies showed that
catheter-based thrombolysis preserves greater venous en-
dothelial function when compared with mechanical throm-
bectomy.6,19 The endothelium is crucial in maintaining
vasomotor reactivity, a function that is mediated in part by
a vasoactive substance such as NO. The presence of venous
thrombus affects production of NO, which in turn may
influence thrombogenicity and vascular vasomotor re-
sponse.25 We recently characterized an endovascular model
of DVT by creating an intraluminal stenosis that reduced
venous flow, with resultant iliac venous thrombosis.10 The
intraluminal stenosis can subsequently be eliminated by
means of balloon angioplasty to restore venous flow. The
present study examined the venous structure and endothe-
lial functions after experimental DVT and assessed the role
of NO in ameliorating the venous endothelial function.
The data from this study demonstrate that supplement-
ing catheter-directed thrombolytic therapy with L-arginine,
the precursor of NO synthesis, results in improved throm-
bolytic efficacy, with ameliorated endothelial function, in a
porcine model of DVT. This was evidenced by enhanced
endothelial-dependent relaxation in the arginine group in
response to both ADP and calcium ionophore A23187.
The mechanism of endothelial-dependent relaxation was
likely modulated by NO-mediated vasoreactive pathways,
inasmuch as previous studies have shown such responses
can be partially inhibited by the NO synthesis inhibitor
NG-monomethyl-L-arginine.19,26
Our findings also reveal that reduction in platelet ag-
gregation occurred in the L-arginine–treated group, along
with a correspondingly elevated local NOx level, when
compared with either the saline or t-PA group. NO, known
as endothelium-derived relaxing factor, is synthesized by
endothelial cells from the terminal guanidino nitrogen
atoms of L-arginine. Under normal circumstances, endo-
thelial cells constantly produce NO.27 The synthesis and
release of NO are also increased by increasing the amount
of precursor, L-arginine.27,28 In addition to its role as a
major regulator of vessel tone, NO inhibits platelet activa-
tion in regulation of hemostasis and thrombosis.7 Numer-
ous studies have documented that blocking production of
NO promotes mechanical injury–induced experimental
thrombosis, whereas increasing synthesis of NO or provid-
ing NO precursors protects against intraluminal thrombo-
sis.15,29
Several studies have examined the possible synergistic
effect of NO and thrombolytic therapy in arterial thrombo-
sis.30,31 A clinical study was performed in patients with
early myocardial infarction and coronary occlusion who
underwent catheter-directed isosorbide dinitrate, an exog-
enous NO donor, and streptokinase thrombolysis.30 Cor-
onary artery recanalization was improved with the combi-
nation therapy compared with thrombolysis alone. In a
study of a canine coronary thrombosis model, continuous
catheter-based infusion of L-arginine at a concentration of
100 g/kg per minute delayed coronary thrombosis and
reduced recurrent thrombosis rates after thrombolytic ther-
apy with t-PA. This study found that the improved throm-
bolytic efficacy as a result of combined L-arginine and t-PA
infusion was associated with decreased collagen-induced
platelet aggregation through increased concentration of
NO.14 Our findings are consistent with those of a recent
report by Kashyap et al,32 who examined the beneficial role
of L-arginine with urokinase thrombolytic therapy in a rat
arterial thrombosis model. Those authors reported that
severe transient endothelial dysfunction, as evidenced by
reduced endothelial-dependent relaxation, was associated
with acute arterial thrombosis. However, administration of
L-arginine in urokinase thrombolysis significantly improved
endothelial-dependent relaxation after acute thrombosis
when compared with urokinase thrombolysis alone. This
improved endothelial function with L-arginine supplemen-
tation was associated with increased NO concentration.
Histologic and electron microscopic findings from our
study revealed similar morphologic endothelial loss as a
result of thrombus exposure or thrombolytic therapy. En-
dothelial loss in the three treatment groups ranged from
36%  18% to 29%  16%, whereas the control group
demonstrated minimal endothelial denudation, at 12% 
8%. Previous investigations of the effects of thrombus on
the vascular endothelium have yielded mixed results. The
presence of thrombosis in an arterialized vein graft signifi-
cantly decreased endothelial function, as evidenced by de-
creased endothelial metabolism of prostacyclin.33 Further-
Table III. Thrombogenicity of iliac veins 14 days after
pulse-spray thrombolytic therapy
Group
Platelet deposition
(platelet/cm2)
Fibrin deposition
(g/cm2)
Sham 4350  2653 5.3  3.4
Saline 19,862  5852 8.7  5.6
t-PA 21,505  6550 11.3  6.2
Arginine 8258  3525* 9.6  5.8
t-PA, Tissue plasminogen activator.
*P  .05 compared with saline and t-PA pulse-spray groups.
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more, the structural integrity of the vein graft showed
morphologic damage to the endothelium after contact with
thrombus for 5 days, but with subsequent partial structural
recovery after thrombectomy. This finding was in contrast
to a report by Whitley et al,34 who studied the effect of
thrombectomy and thrombolysis in a canine femoral arte-
rial thrombosis model. These authors found no significant
changes in endothelium-dependent relaxation or morpho-
logic damage to the endothelium after exposure to throm-
bus for 24 hours. These observations were supported by a
similar study that compared thrombolysis and balloon
thrombectomy in a canine femoral thrombosis model,
which found no significant changes in endothelial architec-
ture after exposure to thrombus for 24 hours.35 The effect
of acute thrombus on venous endothelium was examined
by Cho et al,6 who compared thrombectomy and throm-
bolysis in a canine femoral vein thrombosis model. They
reported that valve competence and endothelial anatomy
were similarly preserved between the two treatment
groups. However, thrombolysis preserved greater endothe-
lial function than did thrombectomy. Moreover, endothe-
lium treated with thrombolysis exhibited reduced throm-
bogenicity, as evidenced by decreased platelet deposition.
The effect of chronic thrombus on venous endothelium
was also studied by the same laboratory.19 They noted
venous endothelium had less residual thrombus 4 weeks
after thrombolysis than with thrombectomy. In addition,
venous thrombolysis maintained a greater degree of struc-
tural endothelial architecture and endothelial-mediated
function, compared with thrombectomy.
Experimental arterial and venous thrombosis studies
have reported increased inflammatory cytokine and adhe-
sion molecule expression.36-38 Moreover, NO-mediated
platelet aggregation occurs in both the arterial and venous
thrombosis models.5,14 However, thrombosis of the arte-
rial system differs significantly from that of the deep venous
system in that the deep venous system is associated with a
Fig 2. Endothelial-dependent response to calcium ionophore
A23187 in porcine iliac veins 14 days after pulse-spray thrombo-
lytic therapy.
Fig 3. Endothelial-dependent response to bradykinin in porcine
iliac veins 14 days after pulse-spray thrombolytic therapy.
Fig 4. Endothelial-dependent response to adenosine diphosphate
(ADP) in porcine iliac veins 14 days after pulse-spray thrombolytic
therapy.
Fig 5. Endothelial-independent response to sodium nitroprusside
(NTP) in porcine iliac veins 14 days after pulse-spray thrombolytic
therapy.
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greater degree of local inflammation and pain.36,38,39 This
disparity may be related to thrombus-induced inflamma-
tion that is partly mediated by leukocyte adhesion to the
venous wall, which is supported in that inhibition of cyto-
kines and adhesion molecules can inhibit the inflammatory
response and recurrent thrombosis in the venous sys-
tem.39-41 A study by Broeders et al8 compared the effect of
NO-mediated thrombosis in a rabbit arterial and venous
system, and found that intraluminal infusion of L-arginine
resulted in significant reduction in thromboembolism in
rabbit venules rather than arterioles. The authors reported
that NO synthase was more important in the thrombotic
process in venules than in arterioles. This finding has been
supported by others who noted that inhibition of NO
synthase induces spontaneous aggregation of platelets and
leukocyte adhesion in venules but not in arterioles.42,43
The effect of L-arginine in modulating vascular patho-
physiology has received increased investigative focus, par-
ticularly as a means of inhibiting atherogenesis and recur-
rent stenosis. Numerous studies have documented the
efficacy of dietary L-arginine supplementation in reduction
of arterial atherogenesis in animals with hypercholesterol-
emia.44-46 Davies et al47 studied the combined effect of oral
L-arginine supplementation and dietary cholesterol reduc-
tion in rabbits with hypercholesterolemia treated with in-
terposition vein bypass grafting. They noted that this com-
bined therapy significantly reduced atheromatous
progression in the vein grafts. In a study that examined the
effect of L-arginine on intimal hyperplasia after iliac artery
balloon angioplasty, Tarry et al48 reported that rabbits fed
an L-arginine–supplemented diet had significantly im-
proved endothelial-dependent relaxation and decreased in-
timal hyperplasia. In a similar study that examined the effect
of iliac balloon angioplasty in rabbits with hypercholester-
olemia a single intramural local delivery of L-arginine sig-
nificantly enhanced local NO production and endothelial-
dependent relaxation at 1 week, and reduced intimal
thickening 4 weeks later.49 These findings were in contrast
to a recent study by Landis et al,50 who studied the effect of
dietary L-arginine on flow-restricted vein graft in a nonhy-
percholesterolemic canine model. They found decreased
vein graft vasoreactivity and no effect on intimal hyperplasia
in animals receiving dietary L-arginine supplementation.
The authors postulated that in a normal nondiseased artery,
dietary L-arginine supplementation could result in a parallel
increase in endogenous NO inhibitor, asymmetric dim-
ethylarginine, and alter L-arginine metabolism through en-
zymatic pathways other than NO synthase. Irrespective of
the vascular disease model, the collective findings from
these studies underscore the potential therapeutic benefit
of augmenting NO activity with L-arginine supplementa-
tion to improve endothelial function and luminal patency
in diseased vasculature.
In summary, our findings suggest that the antiplatelet
effect of NO may have therapeutic benefit in treatment of
DVT. Supplementation of NO precursor, L-arginine, in
catheter-directed thrombolysis improved endothelial vaso-
reactivity and reduced platelet deposition in our experi-
mental DVT model. These data suggest a potential thera-
peutic role for L-arginine in standard thrombolytic therapy
in treatment of DVT.
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